Literature DB >> 10928979

Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.

M S Duxon1, K R Starr, N Upton.   

Abstract

We report here the use of rat high-light social interaction to model the temporal anxiolytic/antidepressant effects of SSRIs seen in the clinic. Compared to vehicle controls, 21, but not 14, days of paroxetine treatment (3 mg kg(-1), p.o., daily) produced a marked increase in rat social interaction (Vehicle=71.3+/-7.3 s; Paroxetine=116.7+/-14.7 s; P<0.01) with no concurrent effect on locomotor activity, consistent with anxiolysis. To assess whether concurrent 5-HT(1A) receptor blockade reduces the time to onset of anxiolysis seen with paroxetine alone (21 days), rats were implanted with osmotic minipumps to continuously infuse the 5-HT(1A) receptor antagonist WAY100635 (1 mg kg(-1) day(-1), s.c., 7 days) alone or in combination with paroxetine (3 mg kg(-1), p.o., daily, 7 days), prior to anxiety testing. Paroxetine (Veh/Par=61.9+/-7.9 s) or WAY100635 (WAY/Veh=71.6+/-4.7 s) alone, had no effect on social interaction time compared to vehicle treated controls (Veh/Veh=76.4+/-4.9 s), whilst coadministration of WAY100635 with paroxetine, produced a marked elevation in social interaction (WAY/Par=149.3+/-16.8 s; P<0.01) relative to all other groups with no concurrent change in locomotor activity. In contrast, acute administration of WAY100635 (0.03 mg kg(-1), s.c.) with paroxetine (3 mg kg(-1), p.o.) did not alter any behavioural measure, suggesting that the anxiolysis induced by the combination after 7 days is attributable to a CNS adaptive response. This data demonstrates that coadministration of a 5-HT(1A) receptor antagonist with paroxetine markedly reduces the latency to anxiolysis, in the rat. This study supports the use of the rat social interaction test to further delineate adaptive changes in the CNS responsible for the anxiolytic/antidepressant action of SSRIs seen in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928979      PMCID: PMC1572240          DOI: 10.1038/sj.bjp.0703496

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients.

Authors:  L Bascara
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

2.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs.

Authors:  S E File
Journal:  J Neurosci Methods       Date:  1980-06       Impact factor: 2.390

4.  Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.

Authors:  E Hollander; C DeCaria; R Gully; A Nitescu; R F Suckow; J M Gorman; D F Klein; M R Liebowitz
Journal:  Psychiatry Res       Date:  1991-01       Impact factor: 3.222

Review 5.  New developments in the treatment of depression.

Authors:  S A Montgomery
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

6.  A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients.

Authors:  K Rickels; J Amsterdam; C Clary; I Fox; E Schweizer; C Weise
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

7.  Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.

Authors:  J Zohar; T R Insel; R C Zohar-Kadouch; J L Hill; D L Murphy
Journal:  Arch Gen Psychiatry       Date:  1988-02

8.  The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat.

Authors:  M D Tricklebank; C Forler; J R Fozard
Journal:  Eur J Pharmacol       Date:  1984-11-13       Impact factor: 4.432

9.  Can social interaction be used to measure anxiety?

Authors:  S E File; J R Hyde
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

10.  A comparison of paroxetine, imipramine and placebo in depressed out-patients.

Authors:  G C Dunbar; J B Cohn; L F Fabre; J P Feighner; R R Fieve; J Mendels; R K Shrivastava
Journal:  Br J Psychiatry       Date:  1991-09       Impact factor: 9.319

View more
  10 in total

1.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

2.  Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.

Authors:  Bríd Aine Nic Dhonnchadha; Nadège Ripoll; Florence Clénet; Martine Hascoët; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Authors:  Inés Artaiz; Arturo Zazpe; Ana Innerárity; Elena Del Olmo; Alvaro Díaz; José Angel Ruiz-Ortega; Elena Castro; Ruth Pena; Luis Labeaga; Angel Pazos; Aurelio Orjales
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 4.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

Review 5.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

6.  Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor.

Authors:  Thomas L Schwartz; Umar A Siddiqui; Stephen M Stahl
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

7.  Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B.

Authors:  Zoë A Hughes; Kathryn R Starr; Claire M Scott; Michael J Newson; Trevor Sharp; Jeannette M Watson; Jim J Hagan; Lee A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.415

8.  Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use.

Authors:  Mandeep Singh; Thomas L Schwartz
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-23       Impact factor: 2.570

Review 9.  Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Psychiatry Investig       Date:  2015-03-18       Impact factor: 2.505

Review 10.  Vilazodone for the Treatment of Depression: An Update.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae
Journal:  Chonnam Med J       Date:  2016-05-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.